Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Quest Partners LLC

Quest Partners LLC grew its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 915.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,201 shares of the company’s stock after purchasing an additional 14,605 shares during the period. Quest Partners LLC’s holdings in Elanco Animal Health were worth $238,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of ELAN. Russell Investments Group Ltd. lifted its position in Elanco Animal Health by 32.8% in the first quarter. Russell Investments Group Ltd. now owns 46,571 shares of the company’s stock valued at $758,000 after buying an additional 11,490 shares during the last quarter. Tidal Investments LLC boosted its position in shares of Elanco Animal Health by 34.6% during the 1st quarter. Tidal Investments LLC now owns 22,575 shares of the company’s stock worth $368,000 after purchasing an additional 5,797 shares during the period. Comerica Bank increased its holdings in Elanco Animal Health by 272.6% in the 1st quarter. Comerica Bank now owns 11,716 shares of the company’s stock valued at $191,000 after purchasing an additional 8,572 shares during the last quarter. Cetera Advisors LLC purchased a new stake in Elanco Animal Health in the first quarter valued at approximately $213,000. Finally, SG Capital Management LLC acquired a new position in Elanco Animal Health during the first quarter worth $4,211,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $13.14 on Wednesday. Elanco Animal Health Incorporated has a 1 year low of $11.40 and a 1 year high of $18.80. The stock has a market capitalization of $6.49 billion, a PE ratio of 33.00, a PEG ratio of 1.39 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a 50-day simple moving average of $13.68 and a 200-day simple moving average of $14.72.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the business posted $0.18 EPS. The firm’s revenue was down 3.6% on a year-over-year basis. On average, analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ELAN shares. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Barclays raised their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $17.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.